Entourage Health Reschedules Full-Year 2022 Earnings Conference Call to Align with First Quarter 2023 Results
April 21 2023 - 4:00PM
Entourage Health Corp.
(TSX-V: ENTG) (OTCQX: ETRGF)
(FSE:4WE) ("Entourage" or the "Company"), a Canadian
producer and distributor of award-winning cannabis products,
announced today that it will file its financial statements and
management’s discussion and analysis for the fourth quarter and
fiscal year ended December 31, 2022, by Monday, May 1, 2023. The
Company will defer its fourth quarter and full-year 2022 conference
call previously scheduled for April 28, 2023, to coincide with its
projected first quarter 2023 financial results, expected on or
before May 30, 2023. Filing and conference call details for first
quarter 2023 will be provided in a subsequent announcement.
For more information, please visit us
at www.entouragehealthcorp.com
About Entourage Health
Corp.
Entourage Health Corp. is the publicly traded
parent Company of Entourage Brands Corp. and CannTx Life Sciences
Inc., licence holders producing and distributing cannabis products
for both the medical and adult-use markets. The Company owns and
operates a state-of-the-art hybrid greenhouse and processing
facility located on 158-acres in Strathroy, ON; a fully licensed
26,000 sq. ft. Aylmer, ON processing facility. With its Starseed
Medicinal medical-centric brand, Entourage has expanded its
multi-channeled distribution strategy. Starseed’s industry-first,
exclusive partnership with LiUNA, the largest construction union in
Canada, along with employers and union groups complements
Entourage’s direct sales to medical patients. With the launch of
Syndicate, Entourage now hosts another unique medical marketplace
that offers patients a collective of Canadian micro-cultivators’
products, along with Entourage’s family of brands. Entourage’s
elite adult-use product portfolio includes Color Cannabis and
Saturday Cannabis – sold across eight provincial distribution
agencies. It is the exclusive Canadian producer and distributor of
award-winning U.S.-based wellness brand Mary’s Medicinals sold in
both medical and adult-use channels. Under a collaboration with The
Boston Beer Company subsidiary, Entourage is also the exclusive
distributor of cannabis-infused beverages ‘TeaPot’ in Canada, which
launched in summer 2022, starting in select provinces. In addition,
Entourage also entered into an exclusive agreement with Irwin
Naturals, a renowned nutraceutical and herbal supplement formulator
of popular branded wellness products sold across North America. The
new line of CBD soft gels is now available on Starseed’s medical
platform.
Follow Entourage and its brands
on LinkedInTwitter: Entourage, Color
Cannabis, Saturday Cannabis, Starseed
& SyndicateInstagram: Entourage, Color
Cannabis, Saturday Cannabis, Starseed, &
Syndicate
For Investor & Media
Enquiries:Catherine FlamanSenior Director, Communications
& Corporate
Affairs416-910-0279Catherine.flaman@entouragecorp.com
Forward Looking Information
This press release contains "forward-looking information" within
the meaning of applicable Canadian securities legislation which are
based upon Entourage's current internal expectations, estimates,
projections, assumptions and beliefs and views of future events.
Forward-looking information can be identified using forward-looking
terminology such as "expect", "likely", "may", "will", "should",
"intend", "anticipate", "potential", "proposed", "estimate" and
other similar words, including negative and grammatical variations
thereof, or statements that certain events or conditions "may",
"would" or "will" happen, or by discussions of strategy.The
forward-looking information in this news release is based upon the
expectations, estimates, projections, assumptions, and views of
future events which management believes to be reasonable in the
circumstances. Forward-looking information includes estimates,
plans, expectations, opinions, forecasts, projections, targets,
guidance, or other statements that are not statements of fact.
Forward-looking information necessarily involve known and unknown
risks, including, without limitation, risks associated with general
economic conditions; adverse industry events; loss of markets;
future legislative and regulatory developments; inability to access
sufficient capital from internal and external sources, and/or
inability to access sufficient capital on favourable terms; the
cannabis industry in Canada generally; the ability of Entourage to
implement its business strategies; the COVID-19 pandemic;
competition; crop failure; and other risks.
Any forward-looking information speaks only as
of the date on which it is made, and, except as required by law,
Entourage does not undertake any obligation to update or revise any
forward-looking information, whether as a result of new
information, future events or otherwise. New factors emerge from
time to time, and it is not possible for Entourage to predict all
such factors. When considering this forward-looking information,
readers should keep in mind the risk factors and other cautionary
statements in Entourage’s disclosure documents filed with the
applicable Canadian securities' regulatory authorities on SEDAR at
www.sedar.com. The risk factors and other factors noted in the
disclosure documents could cause actual events or results to differ
materially from those described in any forward-looking
information.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS
REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE
POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR
THE ADEQUACY OR ACCURACY OF THIS RELEASE
Entourage Health (TSXV:ENTG)
Historical Stock Chart
From Feb 2025 to Mar 2025
Entourage Health (TSXV:ENTG)
Historical Stock Chart
From Mar 2024 to Mar 2025